|
|
||||||||
1 Institute of Human Physiology, University of Pavia, 27100 Pavia; 2 Department of Internal Medicine, Chair of Gastroenterology, Second University of Naples and 4 Department of Cellular and Molecular Biology and Pathology "L. Califano," Institute of Experimental Endocrinology and Oncology "G. Salvatore" of Consiglio Nazionale delle Ricerche, Federico II University, 80131 Naples, Italy; and 3 Institut National de la Santé et de la Recherche Médicale Unité 452, Nice University School of Medicine, 06107 Nice Cedex 2, France
| |
ABSTRACT |
|---|
|
|
|---|
The relationship between nonsteroidal anti-inflammatory drugs (NSAIDs) and Helicobacter pylori-induced gastric mucosal injury is still under debate. VacA toxin is an important H. pylori virulence factor that causes cytoplasmic vacuolation in cultured cells. Whether and how NSAIDs affect VacA-induced cytotoxicity is unclear. This study was designed to evaluate the effect of NSAIDs on H. pylori VacA toxin-induced cell vacuolation in human gastric mucosal cells in culture (MKN 28 cell line). Our data show that 1) NSAIDs (indomethacin, aspirin, and NS-398) inhibit VacA-induced cell vacuolation independently of inhibition of cell proliferation and prostaglandin synthesis; 2) NSAIDs impair vacuole development/maintenance without affecting cell binding and internalization of VacA; and 3) NSAIDs, as well as the chloride channel blocker 5-nitro-2-(3-phenylpropylamino) benzoic acid, also inhibit cell vacuolation induced by ammonia. We thus hypothesize that NSAIDs might protect MKN 28 cells against VacA-induced cytotoxicity by inhibiting VacA channel activity required for vacuole genesis.
aspirin; chloride channel blockers; cyclooxygenases; indomethacin; NS-398
| |
INTRODUCTION |
|---|
|
|
|---|
HELICOBACTER PYLORI (H. pylori) and nonsteroidal anti-inflammatory drugs (NSAIDs) are recognized to cause the large majority of peptic ulcers through apparently different pathological mechanisms (15, 26).
H. pylori-related gastric mucosal injury depends on the inflammatory response of the host and on the release of virulence factors, among which VacA toxin plays a central role (3, 38, 43, 59). VacA is a protein toxin, formed by monomers of ~90 kDa, able to induce cytoplasmic vacuoles in eukaryotic cells in culture (6, 40). Cytoplasmic vacuoles are also present in vivo in the gastric epithelium of H. pylori-colonized patients (10, 11, 53). When given to mice, purified VacA causes gastric epithelial damage closely resembling that found in H. pylori-colonized patients (50). After cell internalization, VacA localizes in the endocytic-endosomal compartment from which vacuoles originate (36, 41, 42). Vacuole development is strictly dependent on the presence in the incubation medium of weak bases like ammonia (which can be generated by H. pylori urease; see Refs. 9 and 42). Recently, it has been reported that VacA may act as a channel-forming toxin, and it has also been proposed that VacA channels play a direct role in cell vacuolation. Endocytosed VacA channels could stimulate the turnover of endosomal vacuolar-type H+-ATPase (V-ATPase) by increasing the permeability of the endosomal membrane to anions (for reviews, see Refs. 40 and 43). This would lead to the accumulation of osmotically active species causing an osmotic imbalance of late endosomes with subsequent vacuole formation.
In patients consuming NSAIDs, abrogation of processes such as maintenance of adequate gastric mucosal blood flow or mucus/bicarbonate secretion, which largely depends on constitutive PG synthesis, plays a key role in the pathogenesis of gastric mucosal injury (15, 55). On the other hand, H. pylori injury to the gastric mucosa occurs despite stimulation of PG synthesis (19, 46).
The relationship between H. pylori and NSAIDs in terms of their effects on gastric mucosa remains controversial. Some clinical studies have reported no interaction between H. pylori and NSAIDs or a protective role of H. pylori in patients given NSAIDs (16, 21, 25). Other studies have shown harmful effects of H. pylori in patients given NSAIDs (1, 4, 23). In vivo experimental studies have shown that NSAIDs revert the increase in apoptosis and proliferation of gastric epithelial cells as well as the inflammatory activity caused by H. pylori (22, 60). The interference of NSAIDs with other H. pylori-related effects in the gastric mucosa is still unknown. In particular, whether and how NSAIDs affect VacA-induced cytotoxicity has not been determined.
This study was designed to evaluate the relationship between NSAIDs and H. pylori VacA toxin in terms of vacuolation of human gastric epithelial cells in culture. Our data show that 1) NSAIDs inhibit VacA-induced cell vacuolation independently of inhibition of cell proliferation and PG synthesis; 2) NSAIDs mainly impair vacuole development/maintenance without affecting cell binding and internalization of VacA; and 3) NSAIDs, as well as the chloride channel blocker 5-nitro-2-(3-phenylpropylamino) benzoic acid (NPPB), also inhibit cell vacuolation induced by ammonia.
| |
MATERIALS AND METHODS |
|---|
|
|
|---|
Human gastric epithelial cells in culture. We used the MKN 28 cell line. This cell line derives from a human gastric tubular adenocarcinoma and shows gastric-type differentiation (18, 45). MKN 28 cells were grown as monolayers in DMEM-Ham's nutrient mixture F-12 (1:1; Sigma, St. Louis, MO) supplemented with 10% FCS (GIBCO-BRL, Paisley, UK) at 37°C in a humidified atmosphere of 5% CO2 in air.
Bacterial broth culture filtrate preparation.
VacA-containing broth culture filtrate (VacA+ BCF) was
produced from H. pylori strain 60190 (ATCC 49503), as
described by Ricci et al. (39, 42). Briefly, bacteria were
grown in Brucella broth (Difco, Detroit, MI) supplemented with 1%
Vitox (Oxoid, Basingstoke, UK) and 5% FCS (GIBCO) for 24-36 h at
37°C under microaerobic conditions and continuous shaking. When
bacterial suspensions reached 1.2 optical density units at 450 nm
(corresponding to a bacterial concentration of 5 × 108 colony-forming units/ml), bacteria were removed by
centrifugation (12,000 g for 10 min), and the supernatant
was sterilized by passage through a 0.22-µm cellulose acetate filter.
BCF was then concentrated 50-fold by using centrifugal filter devices
(Millipore, Bedford, MA). Concentrated VacA+ BCF was stored
at
20°C and used for cell intoxication at a dilution of 1:150. VacA
prepared by this procedure does not require activation by acid/alkaline
treatment (40). The vacuolating power of VacA+
BCF prepared and used as described was equivalent to that exhibited by
a final concentration of 0.4 µg/ml purified VacA.
NSAIDs. We used 1) indomethacin [1-(p-chlorobenzoyl)-5-methoxy-2-methyl-3-indolylacetic acid (Indo); Sigma]; 2) aspirin [2-(acetyloxy)benzoic acid (ASA); Sigma]; and 3) N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide (NS-398; Calbiochem, La Jolla, CA).
Cell vacuolation. Subconfluent monolayers of MKN 28 cells on six-well multiwell tissue culture dishes were incubated for 30 min at 37°C with Hanks' balanced salt solution (HBSS) in the absence or presence of different NSAIDs, PGE2 or arachidonic acid (AA). Then either 4 mM NH4Cl, 4 mM NH4Cl plus VacA+ BCF, or NH4Cl at different concentrations in the absence or presence of VacA+ BCF was added for 16 h. In some experiments, to study the effect of NSAIDs on an already developed VacA-induced cell vacuolation, cells were incubated for 16 h with 4 mM NH4Cl or 4 mM NH4Cl plus VacA+ BCF and then for an additional 8 h in the absence or presence of different NSAIDs (VacA-preloaded protocol). At the end of each experiment, cell vacuolation was quantitated by means of neutral red uptake, carried out in accordance with Cover et al. (7). Results were expressed as micrograms of neutral red per microgram cell protein (41). The protein content of cell monolayers was measured in accordance with Lowry et al. (28). Neutral red is an acidotropic, membrane-permeant amine that accumulates in the vacuolar lumen (7, 32). Neutral red uptake is a widely accepted in vitro assay for H. pylori-induced cell vacuolation (7, 9, 35, 36, 40-42). Vacuolation of variously treated cell monolayers was also evaluated qualitatively using a phase-contrast inverted microscope (Diaphot 300; Nikon, Tokyo, Japan) equipped with a photocamera; representative microscopic fields were photographed by a technical assistant (V. Necchi) unaware of the treatment.
Cell proliferation.
Cell proliferation was assayed as previously described
(39). Briefly, MKN 28 cells were seeded on 24-well
multiwell tissue culture dishes (2 × 104 cells/well).
After seeding (12 h), the FCS-containing medium was removed and
replaced with FCS-free medium to synchronize cell cycles. Later (12 h),
cells were incubated for 24 h in the absence or presence of either
different NSAIDs or 1-
-D-arabinofuranosylcytosine (ARA-C) in medium with dialyzed FCS. Before the end of the incubation (4 h), [3H]thymidine (1.8 µCi/well; Amersham
International, Little Chalfont, UK) was added. At the conclusion of the
incubation period, cells were washed three times with ice-cold PBS,
10% TCA was added, and the precipitate was passed through glass
microfiber filters (Whatman 934 AH) and washed with 100% ethanol.
Filters then were transferred to vials containing 10 ml of
scintillation cocktail (Econofluor; DuPont de Nemours Italiana, NEN
Products, Cologno Monzese, Italy) and counted in a Beckman beta
counter. The results were expressed as a percentage of
[3H]thymidine uptake in control samples (i.e., samples
not treated with NSAIDs or ARA-C).
VacA binding and internalization. Subconfluent monolayers of MKN 28 cells were incubated with HBSS in the absence or presence of different NSAIDs for 30 min at 37°C and then cells were transferred at 4°C for 1 h to block the active cellular processes required for VacA internalization (30). VacA+ BCF was added, and cells were incubated for 30 min at 4°C. At the end of this incubation period, the medium was discarded, and the monolayers were washed three times with ice-cold HBSS. For VacA binding evaluation, cells were then lysed with boiling lysis buffer (1.5 M Tris · HCl, pH 6.8, 8% SDS, and 40% glycerol; supplemented with 20% 2-mercaptoethanol) and collected. For VacA internalization evaluation, cells were then incubated for 4 h at 37°C with HBSS containing 4 mM NH4Cl in the absence or presence of different NSAIDs. As described by McClain et al. (30), increasing the temperature from 4 to 37°C allows bound VacA to become internalized in cells. After 37°C incubation, the medium was discarded, and cells were incubated for 1 h at 4°C with HBSS containing 2 mg/ml Pronase (Calbiochem) to proteolyze extracellular membrane-bound VacA. At the end of this incubation, cells were completely detached from the plastic support by repeated pipetting and centrifuged at 300 g for 2 min at 0°C. Cells were then lysed with boiling lysis buffer and collected. VacA binding and internalization were evaluated by SDS-PAGE followed by Western blotting as previously described (48) using a polyclonal rabbit anti-VacA serum (serum 958; kindly provided by T. L. Cover, Nashville, TN) and the enhanced chemiluminescence (ECL) revelation system (Amersham). VacA immunoreactive band intensity was quantitated by densitometric scanning of ECL-exposed films using a Howtek Scanmaster-3 densitometer with RFL Print software (Pharmacia Biotech, Cologno Monzese, Italy). VacA binding and internalization studies were normalized internally in accordance with McClain et al. (30): for any given experiment, equal amounts of VacA were added to equal numbers of cells, the cells were lysed in equal volumes, and equal volumes of cell lysate were separated by SDS-PAGE.
Assay of cytotoxicity of diphtheria and ricin toxins.
Measurement of cell protein synthesis inhibition by diphtheria toxin
(DT) and ricin toxin (RT) was carried out essentially as described by
Moya et al. (31). Briefly, subconfluent monolayers of MKN
28 cells on 24-well multiwell tissue culture dishes were washed two
times with HBSS and then 0.5 ml of DMEM (GIBCO) containing 2% FCS was
added to each well. Cells were preincubated for 30 min at 37°C in the
absence or presence of ASA or NS-398, and then DT or RT at the final
concentrations of 10
9 or 10
10 M were added,
and the cells were incubated at 37°C. After 16 h of incubation,
the medium was removed, and, after washing, 0.5 ml of an FCS- and
leucine-free medium that contained 0.25 µCi [14C]leucine (Amersham) was added in each well for 2 h. This medium was then removed, and 0.5 ml of 10% TCA was added to
each well. After 2 h at 4°C, the precipitated monolayers were
washed three times with 10% TCA, and 0.5 ml of 1 M NaOH was added to
each well to dissolve the cell monolayer. Solubilized monolayers were
transferred to counting vials containing the scintillation cocktail,
and the radioactivity was counted in a beta counter. The results were expressed as a percentage of [14C]leucine incorporation
in control samples (i.e., samples not treated with toxins).
Statistics. Results were expressed as means ± SE of three independent experiments. The statistical significance of the differences was evaluated by ANOVA followed by Newman-Keuls' Q-test. Data expressed as a percentage of control were analyzed before being normalized vs. control.
| |
RESULTS |
|---|
|
|
|---|
NSAIDs both prevented and reverted VacA-induced cell vacuolation.
Figure 1 shows that either Indo or ASA,
nonselective inhibitors of cyclooxygenase (COX) isoforms, added 30 min
before VacA (i.e., VacA afterloaded protocol), dose-dependently and
significantly (P < 0.05) inhibited VacA-induced
vacuolation of MKN 28 cells, causing an ~55-70% reduction in
neutral red uptake with the highest dose of NSAIDs. A lower dose of
Indo (i.e., 0.01 mM) did not cause any significant inhibition of
neutral red uptake (data not shown). We also tested whether selective
inhibition of COX-2, the inducible isoform of the enzyme responsible
for PG production, exerted similar effects and found that NS-398 (a
highly selective inhibitor of COX-2) caused an inhibition of
VacA-dependent cell vacuolation comparable to that obtained with
nonselective COX inhibitors (Fig. 1).
|
|
NSAID-dependent inhibition of VacA vacuolating activity is not
accounted for by either inhibition of PG synthesis or inhibition of
cell proliferation.
NSAIDs inhibit PG generation by blocking COX activity (15,
55). In particular, at the doses used in the present study, Indo, ASA, or NS-398 inhibit PGE2 production by MKN 28 cells by >70% (Ref. 45 and unpublished observations). To
assess whether the NSAID effect on VacA vacuolating activity might be
the result of inhibition of PG synthesis, we analyzed whether
exogenously added PGE2 or the PG precursor AA counteracted
NSAID-mediated inhibition of VacA-induced cell vacuolation of MKN 28 cells. As shown in Fig. 3, neither
PGE2 nor AA affected NSAID-dependent inhibition of
VacA-induced cell vacuolation.
|
|
|
NSAIDs did not affect VacA cell binding and internalization or the
cytotoxic action of DT and RT in MKN 28 cells.
We investigated whether NSAIDs were able to alter cell intoxication by
VacA impairing either cell binding of this toxin or its internalization
by MKN 28 cells. Figure 6 shows that none of the NSAIDs used in this study impaired either cell binding or
internalization efficiency of H. pylori toxin. A specific
VacA immunoreactive ~90-kDa band was indeed detected in cell protein extracts of VacA-intoxicated cells after both the binding step (Fig.
6A) and after the internalization step (Fig. 6B)
without major differences in band intensity between control untreated (lane a) and NSAID-treated cells (lanes b,
c, and d). Densitometric analysis of ECL-exposed
films confirmed the absence of significant difference in VacA
immunoreactive band intensity between control untreated and
NSAID-treated cells (data not shown). In the binding experiments, the
absence of VacA immunoreactivity in protease-treated cells compared
with protease-untreated cells (Fig. 6A, lane e vs. lane a, respectively) confirmed that all cell-associated
VacA was really extracellularly bound. In the internalization
experiments, a VacA immunoreactive band of slightly higher intensity
was observed in protease-untreated compared with protease-treated cells
(Fig. 6B, lane e vs. lane a,
respectively), suggesting, in agreement with previous findings
(30), that not all bound VacA was internalized.
|
|
NSAIDs or the chloride channel blocker NPPB similarly prevented
both ammonia- and VacA-dependent cell vacuolation.
Altogether the above results suggested that NSAIDs counteracted VacA
vacuolating activity by inhibiting vacuole development/maintenance through a PG production-independent, yet unidentified, mechanism. Moreover, our results showed that NSAIDs exerted no protection against
other protein toxins with intracellular targets. Weak bases, such as
ammonia, are known to cause the formation of cell vacuoles, which are
much smaller than, but qualitatively identical to, those induced by the
concomitant administration of VacA, sharing a common endosomal origin
(Refs. 32 and 41 and unpublished observations). Therefore, the question arises as to whether NSAIDs specifically counteract the vacuolating activity of VacA only or, on
the contrary, NSAIDs are able to also inhibit VacA-independent osmotic
swelling of late endosomes (i.e., VacA-independent vacuole formation).
To address this issue, we tested the effect of NSAIDs on vacuolation of
MKN 28 cells induced by different concentrations of NH4Cl
either in the absence or in the presence of VacA+ BCF.
Moreover, we compared NSAID action with that of NPPB, an NSAID itself
known as a highly specific and powerful inhibitor of VacA action via
its chloride channel-blocking activity (49, 52). Figure
8 shows that ammonia dose-dependently
increased neutral red uptake by MKN 28 cells, and this effect was
markedly potentiated by the presence of VacA. In the absence of
ammonia, VacA did not cause any increase in neutral red uptake. Indo,
ASA, or NS-398 as well as NPPB did not significantly alter basal
neutral red uptake (i.e., in the absence of ammonia) but significantly inhibited the ammonia-dependent increase in neutral red uptake. Moreover, NSAIDs and NPPB, in a very similar manner, greatly reduced the potentiating effect of VacA on the ammonia-dependent increase in
neutral red uptake (Fig. 8).
|
| |
DISCUSSION |
|---|
|
|
|---|
NSAIDs and H. pylori are the major determinants of gastroduodenal ulcerations in humans (15, 26). Whether H. pylori infection exerts beneficial or detrimental effects on NSAID-related gastric toxicity is still controversial (1, 4, 16, 21, 23, 25). We designed this study to assess whether NSAIDs affected cell vacuolation induced by H. pylori VacA cytotoxin in an experimental model where the effects of systemic factors, gastric acid secretion, or inflammatory infiltrate are negligible.
We demonstrated that both Indo and ASA, nonselective inhibitors of COX activity, are able not only to significantly inhibit VacA-induced vacuole formation but also to cause a significant reversion of vacuoles already developed in VacA-intoxicated cells. That NS-398, a highly selective inhibitor of COX-2 isoform, is as effective as Indo and ASA in counteracting VacA vacuolating action may suggest that inhibition of COX-2, more than COX-1, might contribute to NSAID-dependent inhibition of VacA cytotoxicity. However, even though NS-398 is 42-fold more selective for COX-2 than it is for COX-1 (29), based on our results, we cannot completely rule out a role for COX-1 inhibition in the antivacuolating effect of NSAIDs.
The concentrations of NSAIDs used in this study are compatible with in vivo therapeutic doses of the drugs. In fact, one 50-mg tablet of Indo or one 500-mg tablet of ASA in ~50 ml of water give a final instilled concentration of 2.8 and 55 mM, respectively. Moreover, the concentrations of NSAIDs used in vivo in experimental animals range in different studies from 1.7 to 17 mM for Indo (33, 54), from 11 to 130 mM for ASA (17, 56), and from 1.9 to 19 mM for NS-398 (24, 54). The in vivo relevance of our in vitro study depends on the ability of NSAIDs to permeate the mucus layer lining the mucosal surface of the stomach. In this regard, the mucus gel is readily permeated by exogenous damaging agents such as ethanol, NSAIDs, or bile salts (2, 12). Moreover, ASA and other NSAIDs, at the intragastric acidic pH, are largely undissociated (i.e., lipid soluble), being able to permeate the apical cell membrane of surface epithelial cells where they exert their topical effects (12, 20). However, NSAIDs also act on the stomach systemically, following absorption and subsequent delivery to the basolateral membrane of gastric epithelial cells through the gastric microcirculation. Therefore, the results of the present study, conducted in an experimental model where systemic factors such as blood flow are excluded, must be interpreted with caution, also taking into account mucus permeation by drugs.
The main effects of NSAIDs on gastric mucosa are accounted for by inhibition of PG generation through the blockade of COX activity (15, 55, 57). We therefore assessed whether NSAID-dependent inhibition of VacA vacuolating activity might be related to the inhibition of PG synthesis. Our data suggest that the effect of NSAIDs on VacA-induced cell vacuolation was independent of inhibition of PG production because it was completely insensitive to addition of either PGE2 or AA. However, we cannot rule out that additional PGs other than PGE2 may be contributing to these events. That exogenously added PGs did not counteract NSAID action suggests that the effect of NSAID on VacA vacuolation might be contributed to by COX-unrelated mechanisms (58).
VacA-induced vacuole formation in epithelial cells largely depends on the degree of confluency of the cell monolayer, with confluent monolayers exhibiting a highly reduced cell vacuolation compared with subconfluent ones (reviewed in Ref. 37). In addition, in our experience with subconfluent MKN 28 cell monolayers and low doses of VacA, cells at the periphery of cell islets always show vacuoles both much earlier and larger compared with cells occupying inner positions (Fig. 2 and unpublished observations). The hypothesis thus arises that highly proliferating cells are more sensitive to the vacuolating effect of VacA compared with quiescent cells and that NSAID-dependent inhibition of VacA cytotoxicity might be secondary to NSAID antiproliferative action. That the NSAID-unrelated DNA synthesis inhibitor ARA-C, at doses causing an inhibition of cell proliferation very similar to that we observed with NSAIDs, exerted no effect on VacA-induced cell vacuolation of MKN 28 cells rules out this possibility.
Mounting evidence suggests that VacA vacuolating activity requires toxin binding and internalization by eukaryotic cells (reviewed in Ref. 37). Recently, it has been suggested that protein toxin endocytosis may be regulated by the COX pathway (27). We therefore asked whether the NSAID antivacuolating effect might be due to an impairment of the process of cell intoxication by VacA. However, we showed that NSAIDs did not affect VacA binding to the cell plasma membrane nor did they alter VacA internalization efficiency by MKN 28 cells.
To address the question whether NSAIDs were able to protect MKN 28 cells not only against VacA but also against other protein toxins with intracellular targets, we studied the effect of NSAID on DT- and RT-dependent cytotoxicity. These toxins are internalized in the cells, reach their cytoplasmic targets, and inhibit protein synthesis through different mechanisms (reviewed in Refs. 5 and 34). Our data demonstrated that subconfluent MKN 28 cell monolayers were sensitive to inhibition of protein synthesis by both DT and RT. NSAIDs did not exert any protective action against these toxins, thus suggesting that the effect of NSAIDs is specific for VacA toxin.
Both the genesis and the maintenance of cell vacuoles requires a substantial proton pumping activity by endosomal V-ATPase (8, 35). Because proton pumping activity of endosomal V-ATPase generates an electrochemical proton gradient that progressively limits its further activity, endosomal anion-selective channels would play an important role in endosomal acidification, allowing an influx of counterions (like chloride), thus leading to an overall electroneutral transport (14). In this regard, VacA plays a crucial role by forming, at the plasma membrane level, low-conductance, voltage-dependent, anion-selective channels that, after endocytosis and transport to late endosome, would increase the anionic permeability of the endosomal membrane, thus enhancing proton pumping activity (49).
Several chloride channel blockers, such as NPPB, inhibit both channel activity (in patch-clamp experiments) and cell vacuolation (in neutral red uptake experiments) induced by VacA (52). That the NSAIDs we used exhibit structural similarities with NPPB, an NSAID itself (52), may suggest that NSAIDs may counteract VacA cytotoxicity through inhibition of VacA channel activity.
Mounting evidence suggests that VacA is not vacuolating by itself but acts by increasing the vacuolating activity of weak bases like ammonia (9, 42, 48). Weak bases cross cell membranes in an uncharged state and, after trapping by protonation, they induce osmotic swelling of the late endocytic compartment (32, 41, 42 and unpublished observations). Therefore, we investigated whether NSAIDs exerted any effect also on cell vacuoles induced by weak bases alone, where endosomal V-ATPase activity would be favored by endogenous anionic channels only. To this purpose, we investigated the effect of NSAIDs on cell vacuolation induced by ammonia and on VacA-dependent potentiation of ammonia-induced vacuolation. Our finding that Indo, ASA, and NS-398 were able to significantly inhibit ammonia-induced cell vacuolation in the presence or absence of VacA suggests that NSAIDs may also act by inhibiting endogenous anionic channels of the endosomal membrane. In partial support of this concept, we found that the chloride channel blocker NPPB, which is considered a highly specific inhibitor of VacA anionic channel activity (49), also inhibited ammonia-dependent vacuole formation in MKN 28 cells in a manner very similar to that of NSAIDs.
Tombola et al. (52) found that ASA was not able to counteract VacA-induced vacuole formation in the nongastric HeLa cell line. The apparent discrepancy with our results might be accounted for by the different experimental models. In partial support of this hypothesis, we found that, in MKN 28 gastric cells, 0.01 mM NPPB gave a significant inhibition of VacA-induced vacuole formation, whereas a 10-fold higher concentration (i.e., 0.1 mM NPPB) was necessary to obtain comparable effects in HeLa cells (52).
In conclusion, our data show that Indo, ASA, and NS-398 protected MKN 28 cells against VacA-induced cytotoxicity via a mechanism independent of PG production, inhibition of cell proliferation, and cell binding/internalization of VacA. We postulate that NSAIDs may act by inhibiting VacA channel activity and endogenous anionic channels required for vacuole genesis/maintenance. Because VacA is a major determinant of gastric colonization by H. pylori (44, 47, 51) and of H. pylori-related gastroduodenal injury, our data showing a protective effect of NSAIDs against VacA cytotoxicity are in partial support of the theory that NSAIDs and H. pylori may not act synergistically in damaging the gastric mucosa.
| |
ACKNOWLEDGEMENTS |
|---|
We thank T. L. Cover (Nashville, TN) for providing anti-VacA 958 serum. The invaluable technical assistance of V. Necchi in microphotography is gratefully acknowledged. We are deeply indebted to M. Berardone and E. Montini for excellent artwork.
| |
FOOTNOTES |
|---|
This work was supported in part by grants from Associazione Italiana per la Ricerca sul Cancro, Ministero dell'Università e della Ricerca Scientifica e Tecnologica (COFIN 2000 to V. Ricci and R. Zarrilli), Italy, and from the Institut National de la Santé et de la Recherche Médicale, France.
Address for reprint requests and other correspondence: V. Ricci Istituto di Fisiologia umana, Via Forlanini 6, 27100 Pavia, Italy (E-mail: ricci{at}chifis.unipv.it) or M. Romano, Gastroenterologia S.U.N., Via Pansini 5, 80131 Napoli, Italy (E-mail: marco.romano{at}unina2.it).
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
10.1152/ajpgi.00046.2002
Received 6 February 2002; accepted in final form 25 April 2002.
| |
REFERENCES |
|---|
|
|
|---|
1.
Aalykke, C,
Lauritsen JM,
Hallas J,
Reinholdt S,
Krogfelt K,
and
Lauritsen K.
Helicobacter pylori and risk of ulcer bleeding among users of nonsteroidal anti-inflammatory drugs: a case-control study.
Gastroenterology
116:
1305-1309,
1999[ISI][Medline].
2.
Allen, A,
Hutton DA,
Leonard AJ,
Pearson JP,
and
Sellers LA.
The role of mucus in the protection of the gastroduodenal mucosa.
Scand J Gastroenterol
21, Suppl125:
71-77,
1986.
3.
Atherton, JC.
The clinical relevance of strain types of Helicobacter pylori.
Gut
40:
701-703,
1997
4.
Chan, FKL,
Sung JJY,
Chung SCS,
To KF,
Yung MY,
Leung VKS,
Lee YT,
Chan CSY,
Li EKM,
and
Woo J.
Randomised trial of eradication of Helicobacter pylori before nonsteroidal anti-inflammatory drug therapy to prevent peptic ulcers.
Lancet
350:
975-979,
1997[ISI][Medline].
5.
Collier, RJ.
Understanding the mode of action of diphtheria toxin: a perspective on progress during the 20th century.
Toxicon
39:
1793-1803,
2001[Medline].
6.
Cover, TL,
and
Blaser MJ.
Purification and characterization of the vacuolating toxin from Helicobacter pylori.
J Biol Chem
267:
10570-10575,
1992
7.
Cover, TL,
Puryear W,
Perez-Perez GI,
and
Blaser MJ.
Effect of urease on HeLa cell vacuolation induced by Helicobacter pylori cytotoxin.
Infect Immun
59:
1264-1270,
1991
8.
Cover, TL,
Reddy LY,
and
Blaser MJ.
Effects of ATPase inhibitors on the response of HeLa cells to Helicobacter pylori vacuolating toxin.
Infect Immun
61:
1427-1431,
1993
9.
Cover, TL,
Vaughn SG,
Cao P,
and
Blaser MJ.
Potentiation of Helicobacter pylori vacuolating toxin activity by nicotine and other weak bases.
J Infect Dis
166:
1073-1078,
1992[ISI][Medline].
10.
Figura, N.
Helicobacter pylori exotoxins and gastroduodenal diseases associated with cytotoxic strain infection.
Aliment Pharmacol Ther
10, Suppl1:
79-96,
1996[Medline].
11.
Fiocca, R,
Luinetti O,
Villani L,
Chiaravalli AM,
Capella C,
and
Solcia E.
Epithelial cytotoxicity, immune responses, and inflammatory components of Helicobacter pylori gastritis.
Scand J Gastroenterol
29, Suppl205:
11-21,
1994[ISI][Medline].
12.
Garner, A,
Allen A,
and
Rowe PH.
Gastroduodenal mucosal defense mechanisms and the action of non-steroidal anti-inflammatory agents.
Scand J Gastroenterol
22, Suppl127:
29-34,
1987[ISI][Medline].
13.
Garner, JA,
and
Cover TL.
Binding and internalization of Helicobacter pylori vacuolating cytotoxin by epithelial cells.
Infect Immun
64:
4197-4203,
1996[Abstract].
14.
Günther, W,
Lüchow A,
Cluzeaud F,
Vandevalle A,
and
Jentsch TJ.
ClC-5, the chloride channel mutated in Dent's disease, colocalizes with the proton pump in endocytotically active kidney cells.
Proc Natl Acad Sci USA
95:
8075-8080,
1998
15.
Hawkey, CJ.
Personal review: Helicobacter pylori, NSAIDs and cognitive dissonance.
Aliment Pharmacol Ther
13:
695-702,
1999[ISI][Medline].
16.
Hawkey, CJ,
Tulassay Z,
Szczepanski L,
van Rensburg CJ,
Filipowicz-Sosnowska A,
Lanas A,
Wason CM,
Peacock RA,
and
Gillon KRW
Randomised controlled trial of Helicobacter pylori eradication in patients on nonsteroidal anti-inflammatory drugs: HELP NSAIDs study. Helicobacter Eradication for Lesion Prevention.
Lancet
352:
1016-1021,
1998[ISI][Medline].
17.
Henagan, JM,
Schmidt KL,
and
Miller TA.
Prostaglandin prevents aspirin injury in the canine stomach under in vivo but not in vitro conditions.
Gastroenterology
97:
649-659,
1989[ISI][Medline].
18.
Hojo, H.
Establishment of cultured lines of human stomach cancer. Origin and their morphological characteristics.
Niigata Igakukai Zasshi
91:
737-752,
1977.
19.
Hudson, N,
Balsitis M,
Filipowicz B,
and
Hawkey CJ.
Effect of Helicobacter pylori colonisation on gastric mucosal eicosanoid synthesis in patients taking non-steroidal anti-inflammatory drugs.
Gut
34:
748-751,
1993
20.
Kauffman, G.
Aspirin-induced gastric mucosal injury: lessons learned from animal models.
Gastroenterology
96:
606-614,
1989[ISI][Medline].
21.
Kim, JG,
Graham DY,
and
and The Misoprostol Study Group
Helicobacter pylori infection and the development of gastric and duodenal ulcer in arthritic patients receiving chronic NSAIDs therapy.
Am J Gastroenterol
89:
203-207,
1994[ISI][Medline].
22.
Kim, TI,
Lee YC,
Lee KH,
Han JH,
Chon CY,
Moon YM,
Kang JK,
and
Park IS.
Effects of nonsteroidal anti-inflammatory drugs on Helicobacter pylori-infected gastric mucosae of mice: apoptosis, cell proliferation, and inflammatory activity.
Infect Immun
69:
5056-5063,
2001
23.
Konturek, JW,
Dembinski A,
Konturek SJ,
Stachura J,
and
Domschke W.
Infection of Helicobacter pylori in gastric adaptation to continued administration of aspirin in humans.
Gastroenterology
114:
245-255,
1998[ISI][Medline].
24.
Konturek, PC,
Brzozowski T,
Konturek SJ,
Taut A,
Kwiecien S,
Pajdo R,
Sliwowski Z,
and
Hahn EG.
Bacterial lipopolysaccaride protects gastric mucosa against acute injury in rats by activation of genes for cyclooxygenases and endogenous prostaglandins.
Digestion
59:
284-297,
1998[ISI][Medline].
25.
Laine, L,
Harper S,
Simon T,
Bath R,
Johanson J,
Schwartz H,
Stern S,
Quan H,
and
Bolognese J.
A randomised trial comparing the effect of rofecoxib, a cyclooxygenase-2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis.
Gastroenterology
117:
776-783,
1999[ISI][Medline].
26.
Lazzaroni, M,
and
Bianchi Porro G.
Review article: Helicobacter pylori and NSAID gastropathy.
Aliment Pharmacol Ther
15, Suppl1:
22-27,
2001[Medline].
27.
Llorente, A,
van Deurs B,
Garred O,
Eker P,
and
Sandvig K.
Apical endocytosis of ricin in MDCK cells is regulated by the cyclooxygenase pathway.
J Cell Sci
113:
1213-1221,
2000[Abstract].
28.
Lowry, OH,
Rosebrough NJ,
Farr AL,
and
Randall RJ.
Protein measurement with Folin phenol reagent.
J Biol Chem
193:
265-275,
1951
29.
Masferrer, JL,
Zweifel BS,
Manning PT,
Hauser SD,
Leahy KM,
Smith WG,
Isakson PC,
and
Seibert K.
Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic.
Proc Natl Acad Sci USA
91:
3228-3232,
1994
30.
McClain, MS,
Schraw W,
Ricci V,
Boquet P,
and
Cover TL.
Acid activation of Helicobacter pylori vacuolating cytotoxin (VacA) results in toxin internalization by eukaryotic cells.
Mol Microbiol
37:
433-442,
2000[ISI][Medline].
31.
Moya, M,
Dautry-Varsat A,
Goud B,
Louvard D,
and
Boquet P.
Inhibition of coated pit formation in HEp-2 cells blocks the cytotoxicity of diphtheria toxin but not that of ricin toxin.
J Cell Biol
101:
548-559,
1985
32.
Ohkuma, S,
and
Poole B.
Cytoplasmic vacuolation of mouse peritoneal macrophages and the uptake into lysosomes of weakly basic substances.
J Cell Biol
90:
656-664,
1981
33.
Ohno, T,
Yamamoto K,
Takeuchi K,
and
Okabe S.
16,16-Dimethyl prostaglandin E2 protects gastric mucosal surface epithelial cells from indomethacin-induced damage in rats.
Jpn J Pharmacol
43:
213-220,
1987[Medline].
34.
Olsnes, S,
and
Kozlov JV.
Ricin.
Toxicon
39:
1723-1728,
2001[Medline].
35.
Papini, E,
Bugnoli M,
de Bernard M,
Figura N,
Rappuoli R,
and
Montecucco C.
Bafilomycin A1 inhibits Helicobacter pylori-induced vacuolization of HeLa cells.
Mol Microbiol
7:
323-327,
1993[ISI][Medline].
36.
Papini, E,
de Bernard M,
Milia E,
Bugnoli M,
Rappuoli R,
and
Montecucco C.
Cellular vacuoles induces by Helicobacter pylori originate from late endosomal compartments.
Proc Natl Acad Sci USA
91:
9720-9724,
1994
37.
Papini, E,
Zoratti M,
and
Cover TL.
In search of the Helicobacter pylori VacA mechanism of action.
Toxicon
39:
1757-1767,
2001[Medline].
38.
Peek, RM, Jr,
and
Blaser MJ.
Pathophysiology of Helicobacter pylori-induced gastritis and peptic ulcer disease.
Am J Med
102:
200-207,
1997[ISI][Medline].
39.
Ricci, V,
Ciacci C,
Zarrilli R,
Sommi P,
Tummuru MKR,
Del Vecchio Blanco C,
Bruni CB,
Cover TL,
Blaser MJ,
and
Romano M.
Effect of Helicobacter pylori on gastric epithelial cell migration and proliferation in vitro: role of VacA and CagA.
Infect Immun
64:
2829-2833,
1996[Abstract].
40.
Ricci, V,
Galmiche A,
Doye A,
Necchi V,
Solcia E,
and
Boquet P.
High cell sensitivity to Helicobacter pylori VacA toxin depends on a GPI-anchored protein and is not blocked by inhibition of the clathrin-mediated pathway of endocytosis.
Mol Biol Cell
11:
3897-3909,
2000
41.
Ricci, V,
Sommi P,
Fiocca R,
Figura N,
Romano M,
Ivey KJ,
Solcia E,
and
Ventura U.
Cytotoxicity of Helicobacter pylori on human gastric epithelial cells in vitro: role of cytotoxin(s) and ammonia.
Eur J Gastroenterol Hepatol
5:
687-694,
1993.
42.
Ricci, V,
Sommi P,
Fiocca R,
Romano M,
Solcia E,
and
Ventura U.
Helicobacter pylori vacuolating toxin accumulates into the endosomal-vacuolar compartment of cultured gastric cells and potentiates the vacuolating activity of ammonia.
J Pathol
183:
453-459,
1997[ISI][Medline].
43.
Ricci, V,
Sommi P,
and
Romano M.
The vacuolating toxin of Helicobacter pylori: a few answers, many questions.
Digest Liver Dis
32, Suppl3:
S178-S181,
2000.
44.
Ricci, V,
Zarrilli R,
and
Romano M.
Voyage of Helicobacter pylori in human stomach: odyssey of a bacterium.
Digest Liver Dis
34:
2-8,
2002.
45.
Romano, M,
Razandi M,
Sekhon S,
Krause WJ,
and
Ivey KJ.
Human cell line for study of damage to gastric epithelial cells in vitro.
J Lab Clin Med
111:
430-440,
1988[ISI][Medline].
46.
Romano, M,
Ricci V,
Memoli A,
Tuccillo C,
Di Popolo A,
Sommi P,
Acquaviva AM,
Del Vecchio Blanco C,
Bruni CB,
and
Zarrilli R.
Helicobacter pylori up-regulates cyclooxygenase-2 mRNA expression and prostaglandin E2 synthesis in MKN 28 gastric mucosal cells in vitro.
J Biol Chem
273:
28560-28563,
1998
47.
Salama, NR,
Otto G,
Tompkins L,
and
Falkow S.
Vacuolating cytotoxin of Helicobacter pylori plays a role during colonization in a mouse model of infection.
Infect Immun
69:
730-736,
2001
48.
Sommi, P,
Ricci V,
Fiocca R,
Necchi V,
Romano M,
Telford JL,
Solcia E,
and
Ventura U.
Persistence of Helicobacter pylori VacA toxin and vacuolating potential in cultured gastric epithelial cells.
Am J Physiol Gastrointest Liver Physiol
275:
G681-G688,
1998
49.
Szabo, I,
Brutsche S,
Tombola F,
Moschioni M,
Satin B,
Telford JL,
Rappuoli R,
Montecucco C,
Papini E,
and
Zoratti M.
Formation of anion-selective channels in the cell plasma membrane by the toxin VacA of Helicobacter pylori is required for its biological activity.
EMBO J
18:
5517-5527,
1999[ISI][Medline].
50.
Telford, JL,
Ghiara P,
Dell'Orco M,
Comanducci M,
Burroni D,
Bugnoli M,
Tecce MF,
Censini S,
and
Covacci C.
Gene structure of the Helicobacter pylori cytotoxin and evidence of its key role in gastric disease.
J Exp Med
179:
1653-1658,
1994
51.
Tombola, F,
Morbiato L,
Del Giudice G,
Rappuoli R,
Zoratti M,
and
Papini E.
The Helicobacter pylori VacA toxin is a urea permease that promotes urea diffusion across epithelia.
J Clin Invest
108:
929-937,
2001[ISI][Medline].
52.
Tombola, F,
Oregna F,
Brutsche S,
Szabo I,
Del Giudice G,
Rappuoli R,
Montecucco C,
Papini E,
and
Zoratti M.
Inhibition of the vacuolating and anion channel activities of the VacA toxin of Helicobacter pylori.
FEBS Lett
460:
221-225,
1999[ISI][Medline].
53.
Tricottet, V,
Bruneval P,
Vire O,
Camilleri JP,
Bloch F,
Bonte N,
and
Roge J.
Campylobacter-like organisms and surface epithelium abnormalities in active, chronic gastritis in humans: an ultrastructural study.
Ultrastruct Pathol
10:
113-122,
1986[ISI][Medline].
54.
Wallace, JL,
Bak A,
McKnight W,
Asfaha S,
Sharkey KH,
and
MacNaughton WK.
Cyclooxygenase 1 contributes to inflammatory responses in rats and mice: implications for gastrointestinal toxicity.
Gastroenterology
115:
101-109,
1998[ISI][Medline].
55.
Wallace, JL,
and
Bell CJ.
Gastroduodenal mucosal defense.
Curr Opin Gastroenterol
12:
503-511,
1996.
56.
Wallace, JL,
McKnight W,
Del Soldato P,
Baydoun AR,
and
Cirino G.
Anti-thrombotic effects of a nitric oxide-releasing, gastric-sparing aspirin derivative.
J Clin Invest
96:
2711-2718,
1995[ISI][Medline].
57.
Williams, CS,
and
DuBois RN.
Prostaglandin endoperoxide synthase: why two isoforms?
Am J Physiol Gastrointest Liver Physiol
270:
G393-G400,
1996
58.
Yamamoto, Y,
and
Gaynor RB.
Therapeutic potential of inhibition of the NF-kB pathway in the treatment of inflammation and cancer.
J Clin Invest
107:
135-142,
2001[ISI][Medline].
59.
Zarrilli, R,
Ricci V,
and
Romano M.
Molecular response of gastric epithelial cells to Helicobacter pylori-induced cell damage.
Cell Microbiol
1:
93-99,
1999[ISI][Medline].
60.
Zhu, GH,
Yang XL,
Lai KC,
Ching CK,
Wong BCY,
Yuen ST,
Ho J,
and
Lam SK.
Nonsteroidal anti-inflammatory drugs could reverse to Helicobacter pylori-induced apoptosis and proliferation in gastric epithelial cells.
Dig Dis Sci
43:
1957-1963,
1998[ISI][Medline].
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |